Marburg Virus Disease (MVD) Market Outlook

Thelansis’s “Marburg Virus Disease (MVD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Marburg Virus Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Marburg Virus Disease (MVD) Overview

Marburg virus disease (MVD) is a severe, frequently fatal viral haemorrhagic fever caused by Marburg virus, a filovirus closely related to Ebola virus, transmitted to humans through prolonged exposure to infected Rousettus fruit bats in mines or caves, with subsequent human-to-human transmission occurring via direct contact with infected blood, secretions, organs, or other bodily fluids. The pathophysiology involves widespread viral replication within monocytes, macrophages, and dendritic cells, triggering massive cytokine release, endothelial dysfunction, disseminated intravascular coagulation, and multi-organ failure, with viral evasion of innate immune responses contributing to uncontrolled viraemia. Following an incubation period typically spanning two to twenty-one days, patients present abruptly with high fever, severe headache, myalgia, and malaise, progressing to severe gastrointestinal symptoms, a characteristic non-itchy maculopapular rash, and haemorrhagic manifestations including mucosal bleeding and petechiae in advanced disease, with case fatality rates historically ranging from 24% to 88% depending on viral strain and outbreak setting. Diagnosis relies on RT-PCR detection of viral RNA in blood, performed within appropriate biosafety containment given high transmissibility and severity. No specific antiviral therapy or vaccine is currently approved; management is supportive, encompassing aggressive fluid and electrolyte management, blood product support, and treatment of secondary complications within rigorous infection control and isolation protocols. Investigational monoclonal antibody therapies and vaccine candidates remain under active clinical development. Prognosis is poor, particularly with delayed treatment; rapid case identification, contact tracing, community engagement, and strict infection prevention measures are indispensable to outbreak containment.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)